Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


European Perspectives in Multiple Myeloma & CAR-T from EHA 25

Published on: 23.06.2020, 41 min.

In this webinar, Prof. Dr. John Gribben, Prof. Dr. Valentín Ortiz and PD Prof. Dr. Dr. Udo Holtick discuss three practice changing studies on Multiple Myeloma/CAR-T.

Study 1 summarised by Prof. Dr. John Gribben

IXAZOMIB VS PLACEBO AS POST-INDUCTION MAINTENANCE THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) NOT UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT): PHASE 3 TOURMALINE-MM4 TRIAL

Study 2 summarised by Prof. Dr. Valentín Ortiz

IDECABTAGENE
VICLEUCEL (IDE-CEL; BB2121), A BCMA-TARGETED CAR T CELL THERAPY, IN PATIENTS
WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: INITIAL KARMMA RESULTS

Study 3 summarised by PD Prof. Dr. Dr. Udo Holtick

LB2603 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

 

The webinar was independently produced and paid for by the MEDtalks Group of Companies.